Advertisement

Topics

Hepcidin Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $3500

16:06 EST 8 Nov 2017 | BioPortfolio Report Blog

Hepcidin Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP Pipeline Review, H2 2017


Summary


According to the recently published report 'Hepcidin Pipeline Review, H2 2017'; Hepcidin Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP pipeline Target constitutes close to 5 molecules. Out of which approximately 5 molecules are developed by Companies.


Hepcidin Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP Hepcidin is a protein encoded by the HAMP gene. It acts by promoting endocytosis and degradation of ferroportin leading to the retention of iron in iron exporting cells and decreased flow of iron into plasma. It controls the major flows of iron into plasma, absorption of dietary iron in the intestine and recycling of iron by macrophages.


The report 'Hepcidin Pipeline Review, H2 2017' outlays comprehensive information on the Hepcidin Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type; that are being developed by Companies / Universities.


It also reviews key players involved in Hepcidin Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 2 and 1 respectively. Report covers products from therapy areas Hematological Disorders, Genetic Disorders, Immunology and Oncology which include indications Hemochromatosis, Thalassemia, Acute Inflammation, Anemia, Anemia in Chronic Kidney Disease Renal Anemia, Iron Deficiency Anemia, Polycythemia Vera and Sickle Cell Disease.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Hepcidin Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP

The report reviews Hepcidin Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Hepcidin Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP targeted therapeutics and enlists all their major and minor projects

The report assesses Hepcidin Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Hepcidin Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Hepcidin Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Hepcidin Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Hepcidin Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Hepcidin Liver Expressed Antimicrobial Peptide 1 or Putative Liver Tumor Regressor or HAMP Pipeline Review, H2 2017 [Report Updated: 31102017] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Hepatology
Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...

Bioinformatics
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...